1,2,4-Triazole A Privileged Scaffold For The Development Of Potent Antifungal Agents-A Brief Review.

1,2,4-Triazole A Privileged Scaffold For The Development Of Potent Antifungal Agents-A Brief Review.

Curr Top Med Chem. 2020 Jul 04;:

Authors: Tratrat C

Abstract
Over the past decades, a dramatically tremendous rise in invasive fungal infection diseases attributed to the yeast Candida albicans in immunocompromised individuals poses a serious challenging issue. Another alarming concern is the emergence of multi-drug resistant pathogens to the existing medicines due to their overuse and misuse. 25% to 55% mortality, caused by the invasive infection, was recently reported. Despite a large variety of drugs available to treating invasive candidiasis, only two of them containing a 1,2,4-triazole core, fluconazole and itraconazole, are efficient for the infection therapy induced by fungal Candida species. Moreover, the long-term therapy associated with the azole medications has led to an increase in azole resistance and to high risk of toxicity. Despite numerous outstanding achievements in antifungal drug discovery, the development of novel potent antifungal agents in view to develop more potent and safer fungicides and to overcome the resistance problem associated with the actual drugs is becoming the main focus point for medicinal chemists. Thus, the purpose of the present review is to outline the progresses of the last decade in medicinal chemistry research devoted to the 1,2,4-triazole-based derivatives as potential antifungal agents. The structure activity relationship of these compounds is also discussed.

PMID: 32621720 [PubMed - as supplied by publisher]